Your browser doesn't support javascript.
loading
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang, Annsa C; Mehta, Neil; Dodge, Jennifer L; Yao, Francis Y; Terrault, Norah A.
Afiliação
  • Huang AC; Department of Medicine, Division of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
  • Mehta N; Department of Medicine, Division of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
  • Dodge JL; Department of Surgery, University of California San Francisco, San Francisco, CA.
  • Yao FY; Department of Medicine, Division of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
  • Terrault NA; Department of Surgery, University of California San Francisco, San Francisco, CA.
Hepatology ; 68(2): 449-461, 2018 08.
Article em En | MEDLINE | ID: mdl-29476694

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C / Carcinoma Hepatocelular / Neoplasias Hepáticas / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C / Carcinoma Hepatocelular / Neoplasias Hepáticas / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2018 Tipo de documento: Article